Trial Profile
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Diagnostic use; Registrational
- Sponsors Navidea Biopharmaceuticals
- 16 Oct 2016 According to a Norgine Biopharmaceuticals media release, data from this study were presented at the European Association of Nuclear Medicine (EANM) 2016.
- 15 Apr 2015 Results of lymph node detection in oral cancer will be presented at the 2015 American Head & Neck Society Annual Meeting & Translational Research Meeting.
- 25 Mar 2015 According to a Navidea Biopharmaceuticals media release, data from this study were presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting 2015.